Tudor RA - Search Results

1

Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non-Small Cell Lung Cancer.

Gibson AJW, Li H, D'Silva A, Tudor RA, Elegbede AA, Otsuka S, Bebb DG, Cheung WY. Gibson AJW, et al. Among authors: tudor ra. Am J Clin Oncol. 2019 Jan;42(1):75-81. doi: 10.1097/COC.0000000000000483. Am J Clin Oncol. 2019. PMID: 30211724

2

Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.

Gibson AJW, Li H, D'Silva A, Elegbede AA, Tudor RA, Otsuka S, Bebb DG, Cheung WY. Gibson AJW, et al. Among authors: tudor ra. Lung Cancer. 2019 Aug;134:141-146. doi: 10.1016/j.lungcan.2019.06.003. Epub 2019 Jun 6. Lung Cancer. 2019. PMID: 31319972

3

Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancer.

Gibson AJW, D'Silva A, Elegbede AA, Tudor RA, Dean ML, Bebb DG, Hao D. Gibson AJW, et al. Among authors: tudor ra. Asia Pac J Clin Oncol. 2019 Dec;15(6):343-352. doi: 10.1111/ajco.13234. Epub 2019 Sep 4. Asia Pac J Clin Oncol. 2019. PMID: 31486229

4

Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.

Tudor RA, D'Silva A, Tremblay A, MacEachern P, Morris D, Brenner D, Kopciuk K, Bebb DG. Tudor RA, et al. PLoS One. 2017 Aug 4;12(8):e0181867. doi: 10.1371/journal.pone.0181867. eCollection 2017. PLoS One. 2017. PMID: 28777825 Free PMC article.

5

Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.

Gibson AJW, Li H, D'Silva A, Tudor RA, Elegbede AA, Otsuka SM, Bebb DG, Cheung WY. Gibson AJW, et al. Among authors: tudor ra. Med Oncol. 2018 Aug 2;35(9):117. doi: 10.1007/s12032-018-1182-8. Med Oncol. 2018. PMID: 30073425

6

Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011.

Ko JJ, Tudor R, Li H, Liu M, Skolnik K, Boland WK, Macklow J, Morris D, Bebb DG. Ko JJ, et al. Curr Oncol. 2017 Dec;24(6):e486-e493. doi: 10.3747/co.24.3691. Epub 2017 Dec 20. Curr Oncol. 2017. PMID: 29270057 Free PMC article.

7

The use of automated Ki67 analysis to predict Oncotype DX risk-of-recurrence categories in early-stage breast cancer.

Thakur SS, Li H, Chan AMY, Tudor R, Bigras G, Morris D, Enwere EK, Yang H. Thakur SS, et al. PLoS One. 2018 Jan 5;13(1):e0188983. doi: 10.1371/journal.pone.0188983. eCollection 2018. PLoS One. 2018. PMID: 29304138 Free PMC article.

8

Afatinib in advanced pretreated non-small-cell lung cancer- a Canadian experience.

Ezeife DA, Melosky B, Tudor R, Lin S, Lau A, Panzarella T, Leighl NB. Ezeife DA, et al. Curr Oncol. 2018 Oct;25(5):e385-e390. doi: 10.3747/co.25.3914. Epub 2018 Oct 31. Curr Oncol. 2018. PMID: 30464688 Free PMC article.

9

Clinical impact of mutation fraction in epidermal growth factor receptor mutation positive NSCLC patients.

Martin P, Shiau CJ, Pasic M, Tsao M, Kamel-Reid S, Lin S, Tudor R, Cheng S, Higgins B, Burkes R, Ng M, Arif S, Ellis PM, Hubay S, Kuruvilla S, Laurie SA, Li J, Hwang D, Lau A, Shepherd FA, Le LW, Leighl NB. Martin P, et al. Br J Cancer. 2016 Mar 15;114(6):616-22. doi: 10.1038/bjc.2016.22. Epub 2016 Feb 18. Br J Cancer. 2016. PMID: 26889973 Free PMC article. Clinical Trial.

10

Evolution of Symptom Burden of Advanced Lung Cancer Over a Decade.

Sung MR, Patel MV, Djalalov S, Le LW, Shepherd FA, Burkes RL, Feld R, Lin S, Tudor R, Leighl NB. Sung MR, et al. Clin Lung Cancer. 2017 May;18(3):274-280.e6. doi: 10.1016/j.cllc.2016.12.010. Epub 2017 Jan 5. Clin Lung Cancer. 2017. PMID: 28185791

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

14 results

Search Page